Avoid. NVAX scores poorly on both growth (22/100) and value (21/100) metrics, indicating neither compelling expansion nor attractive valuation support. Leadership alignment is middling (55.3/100) without founder-CEO continuity or meaningful insider lock-up, while material IT infrastructure and cybersecurity outsourcing dependencies create operational concentration risk without offsetting competitive advantages.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Novavax, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 26/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Novavax, Inc. (NVAX) at 26/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. NVAX scores poorly on both growth (22/100) and value (21/100) metrics, indicating neither compelling expansion nor attractive valuation support. Leadership alignment is middling (55.3/100) without founder-CEO continuity or meaningful
NVAX's current Stocky Verdict is 26/100, placing it in the "Avoid" band. This composite combines a 22/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Novavax, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Novavax, Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Novavax, Inc.'s Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Novavax, Inc..
Sign up free and unlock the full analysis on NVAX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for NVAX in the app.
